TABLE 3.
HDa | VHH Pairingsb | Protectionc | IC50d | |
---|---|---|---|---|
nm | ||||
JJX21 | RTA-E5 | RTB-B7 | + | 1* |
JNA10 | RTA-F6 | RTB-B7 | + | 0.1 |
JNA11 | RTA-E5 | RTB-D12 | + | 0.1 |
JNA8 | RTA-F6 | RTB-D12 | − | 0.1 |
JNA6 | RTB-B7 | RTB-B7 | − | 0.5 |
JNA2 | RTA-D10 | RTA-D10 | − | 10 |
JNA3 | RTA-E5 | RTA-E5 | − | 1 |
JNA14 | RTA-D10 | RTA-E5 | − | 2 |
aHD, heterodimer or homodimer.
bUnderlining indicates neutralizing VHHs.
cPlus (+) symbol indicates VHHs that passively protected mice against a 10 × LD50 ricin challenge and minus (−) symbol indicates VHHs that did not confer complete protection.
dValue indicates the concentration of VHHs required to neutralize 50% of ricin in a Vero cell cytotoxicity assay. (*) Indicates IC50 values previously published (12).
eValue indicates the effective concentration of VHHs required to achieve 50% maximal binding to ricin, RTA, or RTB for competition ELISAs.